Format

Send to

Choose Destination
J Alzheimers Dis. 2015;48(3):591-5. doi: 10.3233/JAD-150057.

A Nutritional Formulation for Cognitive Performance in Mild Cognitive Impairment: A Placebo-Controlled Trial with an Open-Label Extension.

Author information

1
Framingham State University, Framingham, MA, USA.
2
Knox College, Galesburg, IL, USA.
3
Loyola University Maryland, Baltimore, MD, USA.
4
University of Massachusetts Lowell, Lowell, MA, USA.

Abstract

Thirty-four individuals with mild cognitive impairment were randomized for 6 months to a nutraceutical formulation (NF: folate, alpha-tocopherol, B12, S-adenosyl methioinine, N-acetyl cysteine, acetyl-L-carnitine) or indistinguishable placebo, followed by a 6-month open-label extension in which all individuals received NF. The NF cohort improved in the Dementia Rating Scale (DRS; effect size >0.7) and maintained baseline performance in CLOX-1. The placebo cohort did not improve in DRS and declined in CLOX-1, but during the open-label extension improved in DRS and ceased declining in CLOX-1. These findings extend prior studies of NF efficacy for individuals without cognitive impairment and with Alzheimer's disease.

KEYWORDS:

Aging; Alzheimer’s disease; cognitive performance; dementia; mild cognitive impairment; nutraceutical

PMID:
26402075
DOI:
10.3233/JAD-150057
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center